二丁酰环磷腺苷钙联合瑞舒伐他汀治疗冠心病合并心力衰竭的效果及对NT-proBNP、cTn、Gal-3水平的影响  

Effect of calcium dibutyryladenosine cyclophosphate combined with rosuvastatin on coronary heart disease with heart failure and its influence on NT-pro BNP,cTn and Gal-3 levels

作　　者：屈文静 薛东 刘波 QU Wenjing;XUE Dong;LIU Bo(Emergency Department,Yan'an People's Hospital,Yan'an Shaanxi 716000,China)

机构地区：[1]延安市人民医院急诊科,陕西延安716000

出　　处：《中国急救复苏与灾害医学杂志》2024年第11期1491-1495,共5页China Journal of Emergency Resuscitation and Disaster Medicine

基　　金：陕西省科协青年人才托举计划项目(编号:20200305)。

摘　　要：目的 观察二丁酰环磷腺苷钙(Cal)结合瑞舒伐他汀(Ros)治疗冠心病(CHD)合并心力衰竭(CHF)的效果及对NT-pro BNP、cTn、Gal-3水平的影响。方法 选取2020年1月—2024年1月收治的108例CHD合并CHF患者,根据随机数学表法分为Cal组和Cal+Ros组,各54例,两组均给予常规对症治疗,Cal组加用Cal治疗,Cal+Ros组加用Cal联合Ros治疗。持续治疗3个月后比较两组临床疗效、治疗前后的心功能[左室缩短分数(FS)、心室舒张功能指标E峰/A峰(E/A)、心脏指数(CI)]以及运动耐力(6MWT)、生活质量(MLHFQ)评分、血清学指标[NT-pro BNP、心脏肌钙蛋白(cTn)、半乳糖凝集素-3(Gal-3)]、血清和肽素(Copeptin)、胱抑素C(Cys C)、基质金属蛋白酶-9(MMP-9),记录药物不良反应。结果 Cal+Ros组临床总有效率为90.74%,明显高于Cal组75.93%(χ^(2)=4.267,P=0.039);治疗后,两组FS、E/A、CI均升高(P<0.05),且治疗后Cal+Ros组高于Cal组(P<0.05);治疗后,两组6MWT均升高,MLHFQ均下降(P<0.05),且治疗后组间比较具有显著差异(P<0.05);治疗后,两组NT-pro BNP、cTn I和Gal-3均下降(P<0.05),且治疗后Cal+Ros组低于Cal组(P<0.05);治疗后,两组Copeptin、Cys C、MMP-9均下降(P<0.05),且治疗后Cal+Ros组低于Cal组(P<0.05);两组不良反应总发生率比较无显著差异(χ^(2)=1.091,P=0.296)。结论 Cal联合Ros治疗CHD合并CHF具有确切疗效,明显缓解心肌损伤情况,有效改善患者心功能和运动耐力,提升其生活质量。ObjectiveTo observe the efficacy of calcium dibutyryladenosine cyclophosphate(Cal) combined with rosuvastatin (Ros) in the treatment of coronary artery atherosclerotic heart disease (CHD) complicated with congestive heart failure (CHF),as well as its effects on levels of NT-pro BNP,c Tn,and Gal-3.Methods108 patients with CHD complicated with CHF admitted from January 2021 to January 2024 were selected.By means of the random number table method,they were classified into Cal group and Cal+Ros group,with 54 cases in each group.Both groups received routine symptomatic treatment,and Cal group was added with Cal,and Cal+Ros group was additionally given Cal combined with Ros.The clinical efficacy after 3 months of continuous treatment,cardiac function[left ventricular fractional shortening(FS),ventricular diastolic function index E peak/A peak (E/A),cardiac index (CI)],exercise tolerance (6MWT),quality of life (MLHFQ) score,serological indicators[NT-pro BNP,cardiac troponin (c Tn),galectin-3 (Gal-3)],Copeptin,Cys C and MMP-9 before and after treatment and adverse drug reactions were compared between groups.ResultsThe total clinical effective rate in Cal+Ros group with 90.74% was obviously higher than 75.93% in Cal group (P<0.05).The FS,E/A and CI were risen after treatment (χ~2=4.267,P=0.039),and the Cal+Ros group after treatment had higher FS,E/A and CI (P<0.05).After treatment,6MWT was risen while MLHFQ was declined in both groups (P<0.05),and there were significant differences between groups after treatment (P<0.05).The levels of NT-pro BNP,c Tn I and Gal-3 were declined in both group after treatment (P<0.05),and the levels after treatment were lower compared to Cal group (P<0.05).The levels of Copeptin,Cys C and MMP-9 were declined in both group after treatment (P<0.05),and the levels after treatment were lower compared to Cal group (P<0.05).The total incidence rate of adverse reactions revealed no obvious difference between groups (χ~2=1.091,P=0.296).ConclusionCal combined with Ros has exact efficacy in the treat

关 键 词：二丁酰环磷腺苷钙 瑞舒伐他汀 慢性心力衰竭 治疗效果 

分 类 号：R541.7[医药卫生—心血管疾病]